Background Severe anemia is a common side effect of Pegylated Interferon + Ribavirin (PR) and Telaprevir (TVR) in hepatitis C virus (HCV) genotype 1 patients with advanced fibrosis or cirrhosis (F3–F4). Inosine triphosphatase (ITPA) genetic variants are associated with RBV- induced anemia and dose reduction. Aim To test the association of ITPA polymorphisms rs1127354 and rs7270101 with hemoglobin (Hb) decline, need for RBV dose reduction (RBV DR), erythropoietin (EPO) support and blood transfusions during the first 12 weeks of TVR triple therapy. Materials and Methods 69 consecutive HCV-1 patients (mean age 57 years) with F3-F4 who received PR and TVR were genotyped for ITPA polymorphisms rs1127354 and rs7270101. Estimated ITPA deficiency was graded on severity (0–3, no deficiency/mild/moderate/severe). Results ITPA deficiency was absent in 48 patients (70%), mild in 12 (17%) and moderate in 9 patients (13%). Mean week 4 Hb decline was higher in non ITPA deficient patients (3,85 g/dL) than in mildly or moderately ITPA deficient patients (3,07 g/dL and 1,67 g/dL, p<0.0001). Grade 3–4 anemia developed in 81% non ITPA deficient patients versus 67% mild deficient and 55% moderate deficient patients (p = ns). Grade of ITPA deficiency was not associated with RbvDR (no deficiency: 60%, mild: 58%, moderate: 67%; p = ns), EPO use (no deficiency: 65%, mild: 58%, moderate:56%; p = ns) or need for blood transfusion (no deficiency: 27%, mild: 17%, moderate: 33%; p = ns). Conclusions In patients with F3–F4 chronic hepatitis C receiving TVR based therapy, ITPA genotype does not impact on the management of early anemia.
References
[1]
European Association for Study of Liver (2014) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60(2): 392–420. doi: 10.1016/j.jhep.2014.03.002
[2]
Aghemo A, Degasperi E, Colombo M (2013) Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials. Dig Liver Dis 45(1): 1–7. doi: 10.1016/j.dld.2012.05.002
[3]
Hézode C, Fontaine H, Dorival, Larrey D, Zoulim F, et al. (2013) Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 59(3): 434–41. doi: 10.1016/j.jhep.2013.04.035
[4]
Colombo M, Fernández I, Abdurakhmano D, Ferreira PA, Strasser SI, et al.. (2013) Safety and on treatment efficacy of telaprevir: the early access program for patients with advanced hepatitis C. Gut DOI: 10.1136/gutjnl-2013-305667.
[5]
Werner CR, Franz C, Egetemeyr DP, Malek NP, Laueret UM, et al.. (2013) Efficacy and safety of telaprevir (TVR) triple therapy in a ‘real-life’ cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment. J Viral Hepat DOI: 10.1111/jvh.12145.
[6]
Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, et al. (2013) Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 8(2): e55285. doi: 10.1371/journal.pone.0055285
[7]
Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, et al. (2010) Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 139(4): 1181–9. doi: 10.1053/j.gastro.2010.06.016
[8]
Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, et al. (2013) Inosine triphosphatase deficiency helps predict anemia, anemia management and response in chronic hepatitis C therapy. J Viral Hepat 20(12): 858–66. doi: 10.1111/jvh.12113
[9]
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, et al. (2013) Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol 59(4): 667–74. doi: 10.1016/j.jhep.2013.05.017
[10]
Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, et al. (2011) Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 53(2): 415–21. doi: 10.1002/hep.24058
[11]
Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24(2): 289–93. doi: 10.1002/hep.510240201
[12]
Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, et al. (2003) Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29(12): 1705–13. doi: 10.1016/j.ultrasmedbio.2003.07.001
[13]
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, et al. (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128(2): 343–50. doi: 10.1053/j.gastro.2004.11.018
[14]
Galmozzi E, Facchetti F, Degasperi E, Aghemo A, Lampertico P (2013) Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. J Virol Methods 187(2): 271–3. doi: 10.1016/j.jviromet.2012.11.026
[15]
Hammond K, Jimmerson L, MacBrayne C, Ray M, Bushman L, et al. (2013) Increased plasma and intracellular ribavirin concentrations associated with telaprevir use. Rev Antiv Ther Infect dis 3: 26.
[16]
Boglione L, De Nicolò A, Cusato J, Cariti G, Di Perri G, et al. (2014) Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. J Viral Hepat 21(4): 260–3. doi: 10.1111/jvh.12170
[17]
Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, et al. (2010) ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 464(7287): 405–8. doi: 10.1038/nature08825
[18]
Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, et al. (2011) Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 40(4): 1314–21. doi: 10.1053/j.gastro.2010.12.038
[19]
Sulkowski MS, Roberts S, Afdhal N, Dusheiko G, Di Bisceglie AM, et al. (2011) Ribavirin dose modification in treatment-na？ve and previously treated patients who received telaprevir combination treatment: No impact on sustained virologic response in phase 3. J Hepatol 56: S459–S460. doi: 10.1016/s0168-8278(12)61174-x
[20]
Romero-Gómez M, Berenguer M, Molina E, Calleja JL (2013) Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations. J Hepatol 59(6): 1323–30. doi: 10.1016/j.jhep.2013.07.014
[21]
Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, et al. (2013) Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology 57(3): 974–84. doi: 10.1002/hep.26096
[22]
Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, et al. (2013) Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial. Gastroenterology 145(5): 1035–1044. doi: 10.1053/j.gastro.2013.07.051
